Jeff Halldorson, John Paul Roberts – 19 June 2013 – After the foundation of the National Transplant Organization, Spanish rates of deceased donor donation rapidly outpaced US growth over the decade from 1989 to 1999. An analysis of the following decade, 1999‐2009, demonstrated a markedly flattened growth curve for Spanish deceased donor organ procurement, which increased only 2.4% from 33.6 to 34.4 donors per million population (pmp). In comparison, over the same decade in the United States, the rate of deceased donation increased from 20.9 to 26.3 donors pmp (25.8%).

Michael L. Volk, Meghan Roney, Robert M. Merion – 19 June 2013 – The decision to accept or decline a liver allograft for a patient on the transplant waiting list is complex. We hypothesized that surgeons are not accurate at predicting donor‐specific risks.

Rocío García Garza, Pablo Sarobe, Juana Merino, Juan J. Lasarte, Delia D'Avola, Virginia Belsue, José A. Delgado, Leyre Silva, Mercedes Iñarrairaegui, Bruno Sangro, Jesus J. Sola, Fernando Pardo, Jorge Quiroga, J. Ignacio Herrero – 19 June 2013 – Recipients of liver transplantation (LT) may develop immunological tolerance. Factors predictive of tolerance are not clearly understood.

Sumeet K. Asrani, W. Ray Kim, Erick B. Edwards, Joseph J. Larson, Gabriel Thabut, Walter K. Kremers, Terry M. Therneau, Julie Heimbach – 19 June 2013 – The hospital at which liver transplantation (LT) is performed has a substantial impact on post‐LT outcomes. Center‐specific outcome data are closely monitored not only by the centers themselves but also by patients and government regulatory agencies.

Amol S. Rangnekar, Caitlyn Ellerbe, Valerie Durkalski, Brendan McGuire, William M. Lee, Robert J. Fontana – 18 June 2013 – Functional outcomes for long‐term survivors of acute liver failure (ALF) are not well characterized. The aim of this prospective study was to determine health‐related quality of life in long‐term adult ALF survivors. Acute Liver Failure Study Group registry participants completed the Centers for Disease Control and Prevention Health‐Related Quality of Life 14 and Short Form 36 (SF‐36) questionnaires at 1‐ and/or 2‐year follow‐up study visits.

Jacqueline G. O'Leary, Hugo Kaneku, Linda W. Jennings, Nubia Bañuelos, Brian M. Susskind, Paul I. Terasaki, Göran B. Klintmalm – 18 June 2013 – Preformed donor‐specific human leukocyte antigen antibodies (DSAs) are considered a contraindication to the transplantation of most solid organs other than the liver. Conflicting data currently exist on the importance of preformed DSAs in rejection and patient survival after liver transplantation (LT).

Hassan Bholah, John Bate, Kathryn Rothwell, Mark Aldersley – 15 June 2013

Paul Y. Kwo, A. Joseph Tector – 15 June 2013

Lewis Teperman, Dilip Moonka, Anthony Sebastian, Linda Sher, Paul Marotta, Christopher Marsh, Baburao Koneru, John Goss, Dennis Preston, John P. Roberts, Spare‐the‐Nephron Trial Liver Transplantation Study Group – 15 June 2013 – Mycophenolate mofetil (MMF) and sirolimus (SRL) have been used for calcineurin inhibitor (CNI) minimization to reduce nephrotoxicity following liver transplantation.

Nora Gabriela Cejas, Federico G. Villamil, Javier C. Lendoire, Viviana Tagliafichi, Arturo Lopez, Daniela Hansen Krogh, Carlos A. Soratti, Liliana Bisigniano – 15 June 2013 – In July 2005, Argentina became the first country after the United States to introduce the Model for End‐Stage Liver Disease (MELD) for organ allocation. In this study, we investigated waiting‐list (WL) outcomes (n = 3272) and post–liver transplantation (LT) survival in 2 consecutive periods of 5 years before and after the implementation of a MELD‐based allocation policy.